Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 49

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 49
---
 public price of the shares to be sold by the Selling Shareholders following
the quotation of our Common Stock on the OTCQX or the OTCQB marketplace of OTC Market or until the shares of our Common Stock are listed
on a national securities exchange will be at the then-prevailing market price. As a result, purchasers of shares from the Selling
Shareholders could pay more or less per share than investors in the firm commitment underwritten offering who will have purchased Units
at a fixed price. In addition, rapid market sales or sales in significant volumes of the shares by the Selling Shareholders may significantly
dilute the value of our common stock held by investors in our primary offering, resulting in depreciation of the value of shares purchased
at a fixed price per Unit paid by investors in the primary offering and/or significant volatility in the price of our shares.

<div align='center'>25</div>

The sale of shares of our Common Stock by Selling Stockholders could cause the price of our Common Stock to fall and the issuance and sale of Common Stock upon exercise of warrants by Selling Stockholders will cause dilution. The issuance of our Common Stock by the Company in the Primary Offering and upon exercise of our outstanding warrants in this Offering will cause immediate and substantial dilution.

Sales of a substantial
number of shares of our Common Stock by Selling Stockholders in the public market, or the perception that these sales might occur, could
depress the market price of our Common Stock and could impair our ability to raise capital through the sale of additional equity securities.
We are unable to predict the effect that sales may have on the prevailing market price of our Common Stock. In addition, the issuance
of shares of our Common Stock in the Primary Offering and upon exercise of the IPO Warrants and the Investor Warrants by the Selling
Stockholders will result in immediate and substantial dilution to the interests of other existing stockholders since the holders of the
warrants may ultimately receive and sell the full number of shares issuable in connection with exercise of such warrants. If the holders
of the warrants choose to do this, it will cause substantial dilution for the holders of our Common Stock.

Article VIII of our Bylaws designates the appropriate state or federal court in Nevada as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, and therefore may limit our shareholders’ ability to choose a forum for disputes with us or our directors, officers, employees, or agents.

Article VIII of our
By